Results 131 to 140 of about 28,025 (230)

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies

MedComm, Volume 7, Issue 5, May 2026.
Tumors are no longer viewed as sterile but dynamic ecosystems harboring low‐biomass intratumoral microbiota. These microbes, derived from gut, oral cavity, or circulation, shape tumorigenesis and therapy response via core mechanisms: immunomodulation (regulating T cells, macrophages), metabolic reprogramming (SCFAs, indoles, bile acids), chronic ...
Haoling Zhang, Zengkan Du, Ping Lu, Aimin Jiang, Yadong Guo, Yawei Liu, Zhijing Song, Bing Dai, Wangzheqi Zhang   +8 more
wiley   +1 more source

Population Pharmacokinetics and Pharmacokinetics‐Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Elafibranor 80 mg/day is approved for second‐line primary biliary cholangitis (PBC) treatment. We present pharmacokinetic (PK) analyses of elafibranor and its metabolite, GFT1007, and pharmacokinetic‐pharmacodynamic (PKPD) analyses describing the relationship between their exposure and responses in alkaline phosphatase (ALP) and total ...
Qing Xi Ooi, Karl Brendel, Stijn van Beek, Jurij Aguiar Zdovc, Maddlie Bardol, Marion Dehez   +5 more
wiley   +1 more source

Are Postprandial Bile Acid Levels Helpful in Predicting Perinatal Complications in Patients with Intrahepatic Cholestasis of Pregnancy?

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2015
Purpose: To determine the outcomes of Iintrahepatic cholestasis of pregnancy and the role of postprandial serum bile acid levels in the prediction of perinatal complications.
Kudret Erkenekli, Can Tekin iskender, Hasan Onur Topcu, Tugba Ensari, Dilek Uygur, Nuri Danisman   +5 more
doaj  

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background Portal vein thrombosis (PVT) is a common sequela of cirrhosis. Despite regression of fibrosis/cirrhosis observed among some patients after disease‐specific treatment, few studies have considered the role of treatment and response on risk of PVT among patients with cirrhosis across different liver disease states.
Humberto C. Gonzalez, Stuart C. Gordon, Sheri Trudeau, Trueman Wu, Lora Rupp, Christina Melkonian, Mark A. Schmidt, Yihe G. Daida, Amandeep K. Sahota, Christopher L. Bowlus, Mei Lu   +10 more
wiley   +1 more source

PERBEDAAN DERAJAT FIBROSIS HEPAR TIKUS WISTAR YANG DILAKUKAN LIGASI DUKTUS KOLEDOKUS ANTARA KELOMPOK PEMBERIAN KOMBINASI UDCAGLUTATHIONE DENGAN PEMBERIAN TUNGGAL UDCA [PDF]

, 2016
Background: Cholestasis leads liver cell death, fibrosis, cirrhosis, and eventually liver failure. Despite limited benefits, ursodeoxycholic acid (UDCA) is the only Food and Drug Administration–approved treatment for cholestatic disorders.
Khairunnisa, Novita Ikbar, Pawitra , Ika, Prasetyo, Agung Aji   +2 more
core   +1 more source

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background & Aims Baseline alkaline phosphatase (ALP) levels can influence the likelihood of achieving dichotomous biochemical response criteria in primary biliary cholangitis (PBC). This concept was explored using Week 52 data from the phase III ELATIVE trial (NCT04526665), which assessed elafibranor, a peroxisome proliferator‐activated ...
Cynthia Levy, Christopher L. Bowlus, Eric Lawitz, Nuno Antunes, Benjamin Miller, Jianfen Shu, Claudia O. Zein, Kris V. Kowdley   +7 more
wiley   +1 more source

Diagnostic and Prognostic Values of Bile Biomarkers for Malignant Biliary Stenosis

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Introduction Differentiating between malignant and benign biliary strictures remains a clinical challenge because current diagnostic tools have limited sensitivity. The detection of tumour‐related biomarkers directly in bile, which is in close contact with the lesion, may enhance diagnostic accuracy.
E. Gigante, V. Untereiner, S. Caruso, R. Rhaiem, L. Grados, C. Boulagnon‐Rombi, S. Adam, G. D. Sockalingum, R. Garnotel, G. Thiefin   +9 more
wiley   +1 more source

Central blood volume in cirrhosis [PDF]

, 1993
Bendtsen, Flemming, Gerbes, Alexander L., Henriksen, Jens H.   +2 more
core   +1 more source